BDTX.NASDAQBlack Diamond Therapeutics, INC

10-Q: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Clinical Program Updates

Sentiment:

Quarterly Report

📋All filings for Black Diamond Therapeutics, INC
🔒Login to Follow

Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024, while providing updates on its clinical programs for BDTX-1535 and BDTX-4933.

Capital raiseThe company states that it will need substantial additional funding to support its continuing operations and pursue its growth strategy.The company may seek additional capital through public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties or through other sources of financing.The company sold 800,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds of approximately $4.0 million ($3.9 million net of offering costs).In April 2024, the Company sold 1,000,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds of approximately $5.4 million ($5.3 million net of offering costs).In May 2024, the Company sold 2,690,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds of approximately $15.6 million ($15.3 million net of offering costs).
Worse than expectedThe company reported a net loss of $18.2 million, indicating that the company is not yet profitable and is still in the development stage.

Summary

  • Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024, compared to a net loss of $20.9 million for the same period in 2023.
  • The company's research and development expenses were $13.5 million for the quarter, a decrease from $14.8 million in the prior year.
  • General and administrative expenses were $6.7 million, slightly down from $6.8 million in the first quarter of 2023.
  • The company's cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024.
  • Black Diamond believes its current funds will support operations into the third quarter of 2025.
  • The company is advancing clinical trials for BDTX-1535, a brain-penetrant EGFR inhibitor, and BDTX-4933, a brain-penetrant RAF inhibitor.
  • The company expects to announce results from the secondand third-line cohorts of the BDTX-1535 Phase 2 trial in the third quarter of 2024 and results from the first-line cohort in the first quarter of 2025.
  • An update on the BDTX-4933 Phase 1 clinical trial is anticipated in the fourth quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical programs and has a reasonable cash runway, it is still operating at a loss and requires additional funding. The sentiment is neutral to slightly negative due to the ongoing losses and the need for future capital raises.

Positives

  • The company's net loss decreased compared to the same period last year.
  • Research and development expenses decreased, indicating potential cost efficiencies.
  • The company has a substantial cash position of $115.2 million.
  • Clinical trials for BDTX-1535 and BDTX-4933 are progressing with anticipated data readouts in the near future.
  • The company has sufficient funds to operate into the third quarter of 2025.

Negatives

  • The company continues to operate at a loss, with a net loss of $18.2 million for the quarter.
  • The company has an accumulated deficit of $435.7 million as of March 31, 2024.
  • The company is dependent on raising additional capital to fund its operations.

Risks

  • The company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry.
  • There is no assurance that the company's research and development will be successful or that any products developed will obtain necessary regulatory approval.
  • The company is dependent on the services of its employees, consultants, and service providers.
  • The company may not be able to obtain financing on acceptable terms, or at all.
  • The company's future funding requirements will depend on the progress of its clinical trials and regulatory approvals.
  • The company is exposed to macroeconomic conditions and market volatility.

Future Outlook

The company expects its current cash, cash equivalents, and investments to fund operations into the third quarter of 2025. The company anticipates increased expenses as it advances clinical trials and prepares for potential commercialization. The company will need to raise additional capital to support its continuing operations and pursue its growth strategy.

Management Comments

  • The company is advancing two clinical-stage programs: BDTX-1535 and BDTX-4933.
  • The company believes that BDTX-1535 has the potential to treat newly diagnosed patients with EGFRm NSCLC, as well as those with recurrent disease.
  • The company is assessing the potential development of BDTX-1535 for patients with EGFRm NSCLC following adjuvant treatment with osimertinib.
  • The company plans to present Phase 1 dose escalation data and window of opportunity results at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024.
  • The company initiated a Phase 1 clinical trial for BDTX-4933 in the second quarter of 2023.
  • The company expects to announce results from the secondand third-line cohorts of the BDTX-1535 Phase 2 trial in the third quarter of 2024 and results from the first-line cohort in the first quarter of 2025.
  • An update on the BDTX-4933 Phase 1 clinical trial is anticipated in the fourth quarter of 2024.

Industry Context

The company is operating in the competitive oncology therapeutics market, focusing on precision medicine approaches targeting specific genetic mutations. The company's focus on brain-penetrant therapies addresses a significant unmet need in treating cancers that metastasize to the central nervous system. The company's approach to targeting families of oncogenic mutations aligns with the broader industry trend towards personalized medicine.

Comparison to Industry Standards

  • Black Diamond Therapeutics is developing targeted therapies similar to other companies in the precision oncology space, such as Blueprint Medicines and Loxo Oncology (now part of Eli Lilly).
  • The company's focus on brain-penetrant inhibitors is comparable to companies like DelMar Pharmaceuticals, which is developing therapies for glioblastoma.
  • The company's approach to targeting a broad spectrum of mutations within a family is similar to the strategy of companies like Relay Therapeutics, which focuses on allosteric modulation.
  • The company's financial results are typical for a clinical-stage biotech company, with significant R&D expenses and no product revenue.
  • The company's cash runway into the third quarter of 2025 is comparable to other companies at a similar stage of development, but the need for additional capital is a common challenge.

Stakeholder Impact

  • Shareholders may experience dilution if the company raises additional capital through equity offerings.
  • Employees are likely to be impacted by the company's financial performance and any potential restructuring or cost-cutting measures.
  • Customers (potential patients) may benefit from the development of new therapies.
  • Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

  • The company will continue to advance clinical trials for BDTX-1535 and BDTX-4933.
  • The company expects to announce results from the secondand third-line cohorts of the BDTX-1535 Phase 2 trial in the third quarter of 2024.
  • The company expects to announce results from the first-line cohort of the BDTX-1535 Phase 2 trial in the first quarter of 2025.
  • The company anticipates an update on the BDTX-4933 Phase 1 clinical trial in the fourth quarter of 2024.
  • The company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements.

Key Dates

DateDescription
December 2014The company was originally organized as a limited liability company under the name ASET Therapeutics LLC.
September 2016The company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc.
January 2018The company changed its name to Black Diamond Therapeutics, Inc.
January 14, 2020The 2020 Stock Option and Incentive Plan and the 2020 Employee Stock Purchase Plan were approved by the company's stockholders.
February 3, 2020The company completed its initial public offering (IPO).
August 1, 2020The lease on the first floor of the company's Cambridge, MA office commenced.
March 9, 2021The lease on the second floor of the company's Cambridge, MA office commenced.
August 26, 2021The lease for the company's New York, NY office and laboratory space commenced.
November 14, 2022The company filed a shelf registration statement on Form S-3 with the SEC.
November 22, 2022The shelf registration statement became effective.
December 12, 2022The company entered into a sublease for one floor of its Cambridge, Massachusetts office space.
July 5, 2023The company completed an underwritten public offering of 15,000,000 shares of its common stock.
October 10, 2023Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.
April 2024The company described real world evidence of the evolving EGFR mutation landscape at the American Association of Cancer Research (AACR) annual meeting.
June 1, 2024The company plans to present Phase 1 dose escalation data and window of opportunity results at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Third quarter 2024The company expects to announce results from the secondand third-line cohorts of the BDTX-1535 Phase 2 trial.
Fourth quarter 2024An update on the BDTX-4933 Phase 1 clinical trial is anticipated.
First quarter 2025The company expects to announce results from the first-line cohort of the BDTX-1535 Phase 2 trial.

Keywords

oncology, clinical trials, EGFR inhibitor, RAF inhibitor, BDTX-1535, BDTX-4933, non-small cell lung cancer, glioblastoma, cancer, biotechnology, pharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.